TAS-102 with or without bevacizumab in patients with chemorefractory metastatic colorectal cancer: an investigator-initiated, open-label, randomised, phase 2 trial
Pfeiffer, Per, Yilmaz, Mette, Möller, Sören, Zitnjak, Daniela, Krogh, Merete, Petersen, Lone Nørgård, Poulsen, Laurids Østergaard, Winther, Stine Braendegaard, Thomsen, Karina Gravgaard, Qvortrup, Camilla
Published in The lancet oncology (01.03.2020)
Published in The lancet oncology (01.03.2020)
Get full text
Journal Article
Randomized study evaluating trifluridine/tipiracil (TAS-102) versus + trifluridine/tipiracil + bevacizumab as last-line therapy in patients with chemorefractory unresectable metastatic colorectal cancer (mCRC)
Pfeiffer, Per, Yilmaz, Mette, Möller, Sören, Maltha, Line, Krogh, Merete, Zitnjak, Daniela, Szameitat, Caroline Lemb, Hejlesen, Finn, Thomsen, Karina Gravgaard, Qvortrup, Camilla
Published in Journal of clinical oncology (01.02.2019)
Published in Journal of clinical oncology (01.02.2019)
Get full text
Journal Article